$114 Million is the total value of Euclidean Capital LLC's 10 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 9.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INDA | Buy | ISHARES TRmsci india etf | $47,237,668 | +96.1% | 1,200,144 | +107.9% | 41.45% | +83.9% |
| ME | 23ANDME HOLDING CO | $23,354,318 | +5.6% | 10,243,122 | 0.0% | 20.49% | -1.0% | |
| PMVP | PMV PHARMACEUTICALS INC | $11,147,056 | -45.2% | 2,336,909 | 0.0% | 9.78% | -48.6% | |
| RAPT | RAPT THERAPEUTICS INC | $7,943,715 | -7.3% | 432,900 | 0.0% | 6.97% | -13.1% | |
| FHTX | FOGHORN THERAPEUTICS INC | $7,819,818 | -2.8% | 1,261,261 | 0.0% | 6.86% | -8.9% | |
| ALEC | ALECTOR INC | $6,071,734 | -32.9% | 980,894 | 0.0% | 5.33% | -37.1% | |
| ORIC | ORIC PHARMACEUTICALS INC | $4,261,035 | -3.2% | 747,550 | 0.0% | 3.74% | -9.2% | |
| NGM | NGM BIOPHARMACEUTICALS INC | $3,046,430 | -18.7% | 746,674 | 0.0% | 2.67% | -23.8% | |
| TENAYA THERAPEUTICS INC | $2,609,759 | +41.8% | 915,705 | 0.0% | 2.29% | +33.0% | ||
| SURROZEN INC | $483,384 | +3.5% | 802,963 | 0.0% | 0.42% | -3.0% | ||
| FFBC | Exit | FIRST FINL BANCORP OH | $0 | – | -173,576 | -100.0% | -3.94% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PMV PHARMACEUTICALS INC | 12 | Q3 2023 | 54.4% |
| FOGHORN THERAPEUTICS INC | 12 | Q3 2023 | 16.4% |
| NGM BIOPHARMACEUTICALS INC | 12 | Q3 2023 | 14.5% |
| ALECTOR INC | 12 | Q3 2023 | 11.5% |
| RAPT THERAPEUTICS INC | 12 | Q3 2023 | 9.7% |
| ORIC PHARMACEUTICALS INC | 12 | Q3 2023 | 10.0% |
| TENAYA THERAPEUTICS INC | 9 | Q3 2023 | 9.9% |
| FIRST FINL BANCORP OH | 9 | Q4 2022 | 3.9% |
| SURROZEN INC | 9 | Q3 2023 | 2.9% |
| 23ANDME HOLDING CO | 7 | Q3 2023 | 27.2% |
View Euclidean Capital LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| PMV Pharmaceuticals, Inc. | February 14, 2022 | 2,336,909 | 5.1% |
View Euclidean Capital LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR/A | 2023-12-01 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Euclidean Capital LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.